2,838 results on '"RENIN-angiotensin system"'
Search Results
2. Decoding Angiotensin Receptors: TOMAHAQ-Based Detection and Quantification of Angiotensin Type-1 and Type-2 Receptors.
- Author
-
Cosarderelioglu C, Kreimer S, Plaza-Rodriguez AI, Iglesias PA, Talbot CC Jr, Siragy HM, Carey RM, Ubaida-Mohien C, O'Rourke B, Ferrucci L, Bennett DA, Walston J, and Abadir P
- Subjects
- Humans, Aged, Renin-Angiotensin System, Angiotensin Receptor Antagonists, Antibodies, Angiotensins, Receptors, Angiotensin
- Abstract
Background The renin-angiotensin system plays a crucial role in human physiology, and its main hormone, angiotensin, activates 2 G-protein-coupled receptors, the angiotensin type-1 and type-2 receptors, in almost every organ. However, controversy exists about the location, distribution, and expression levels of these receptors. Concerns have been raised over the low sensitivity, low specificity, and large variability between lots of commercially available antibodies for angiotensin type-1 and type-2 receptors, which makes it difficult to reconciliate results of different studies. Here, we describe the first non-antibody-based sensitive and specific targeted quantitative mass spectrometry assay for angiotensin receptors. Methods and Results Using a technique that allows targeted analysis of multiple peptides across multiple samples in a single mass spectrometry analysis, known as TOMAHAQ (triggered by offset, multiplexed, accurate mass, high resolution, and absolute quantification), we have identified and validated specific human tryptic peptides that permit identification and quantification of angiotensin type-1 and type-2 receptors in biological samples. Several peptide sequences are conserved in rodents, making these mass spectrometry assays amenable to both preclinical and clinical studies. We have used this method to quantify angiotensin type-1 and type-2 receptors in postmortem frontal cortex samples of older adults (n=28) with Alzheimer dementia. We correlated levels of angiotensin receptors to biomarkers classically linked to renin-angiotensin system activation, including oxidative stress, inflammation, amyloid-β load, and paired helical filament-tau tangle burden. Conclusions These robust high-throughput assays will not only catalyze novel mechanistic studies in the angiotensin research field but may also help to identify patients with an unbalanced angiotensin receptor distribution who would benefit from angiotensin receptor blocker treatment.
- Published
- 2023
- Full Text
- View/download PDF
3. Renal artery occlusive disease, renin-angiotensin-aldosterone, inflammation, and refractory arterial hypertension, a half-century's perspective.
- Author
-
Stanley JC
- Subjects
- Aldosterone, Angiotensin II, Blood Pressure, Humans, Inflammation, Renal Artery, Renin, Renin-Angiotensin System, Angiotensins, Hypertension diagnosis, Hypertension drug therapy
- Published
- 2022
- Full Text
- View/download PDF
4. Functional ACE2 deficiency leading to angiotensin imbalance in the pathophysiology of COVID-19.
- Author
-
Cook JR and Ausiello J
- Subjects
- Humans, Pandemics, Renin-Angiotensin System, SARS-CoV-2, Angiotensin-Converting Enzyme 2 deficiency, Angiotensins, COVID-19 physiopathology
- Abstract
SARS-CoV-2, the virus responsible for COVID-19, uses angiotensin converting enzyme 2 (ACE2) as its primary cell-surface receptor. ACE2 is a key enzyme in the counter-regulatory pathway of the broader renin-angiotensin system (RAS) that has been implicated in a broad array of human pathology. The RAS is composed of two competing pathways that work in opposition to each other: the "conventional" arm involving angiotensin converting enzyme (ACE) generating angiotensin-2 and the more recently identified ACE2 pathway that generates angiotensin (1-7). Following the original SARS pandemic, additional studies suggested that coronaviral binding to ACE2 resulted in downregulation of the membrane-bound enzyme. Given the similarities between the two viruses, many have posited a similar process with SARS-CoV-2. Proponents of this ACE2 deficiency model argue that downregulation of ACE2 limits its enzymatic function, thereby skewing the delicate balance between the two competing arms of the RAS. In this review we critically examine this model. The available data remain incomplete but are consistent with the possibility that the broad multisystem dysfunction of COVID-19 is due in large part to functional ACE2 deficiency leading to angiotensin imbalance with consequent immune dysregulation and endothelial cell dysfunction., (© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
5. Renin-angiotensin system in intestinal inflammation-Angiotensin inhibitors to treat inflammatory bowel diseases?
- Author
-
Salmenkari H, Korpela R, and Vapaatalo H
- Subjects
- Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Angiotensins pharmacology, Angiotensins therapeutic use, Animals, Antihypertensive Agents therapeutic use, Colitis drug therapy, Drug Evaluation, Preclinical, Fibrosis, Humans, Hypertension drug therapy, Inflammatory Bowel Diseases complications, Mice, Models, Animal, Retrospective Studies, Angiotensins antagonists & inhibitors, Inflammation drug therapy, Inflammatory Bowel Diseases drug therapy, Renin-Angiotensin System drug effects
- Abstract
Inflammatory bowel diseases (IBDs) are chronic disorders of the gastrointestinal tract, which manifest in recurring gastrointestinal inflammation. The current treatment options of IBD are not curative and are lacking in aspects like prevention of fibrosis. New treatment options are needed to fulfil the unmet needs and provide alternatives to drugs with resistances and side effects. Drugs targeting the renin-angiotensin system (RAS), besides being antihypertensive, also possess anti-inflammatory and antifibrotic properties and could offer an inexpensive alternative to control inflammation and fibrosis in the gut. RAS inhibitors have been effective in preventing and alleviating colitis in preclinical studies, but available human data are still sparse. This review outlines the pathophysiological functions of RAS in the gut and summarizes preclinical studies utilizing pharmacological RAS inhibitors in the treatment of experimental colitis. We discuss the alterations in intestinal RAS and the available evidence of the benefits of RAS inhibitors for IBD patients. Retrospective studies comparing IBD patients using ACE inhibitors or angiotensin II receptor blockers have provided optimistic results regarding a milder disease course and fewer hospitalizations and corticosteroid use in patients using RAS inhibitors. Prospective studies are needed to evaluate the effectiveness of these promising medications in the treatment of IBD., (© 2021 The Authors. Basic & Clinical Pharmacology & Toxicology published by John Wiley & Sons Ltd on behalf of Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).)
- Published
- 2021
- Full Text
- View/download PDF
6. Estrogen Deficiency and Colonic Function: Surgical Menopause and Sex Differences in Angiotensin and Dopamine Receptor Interaction.
- Author
-
Garrido-Gil P, Rodriguez-Perez AI, Lage L, and Labandeira-Garcia JL
- Subjects
- Animals, Female, Male, Mice, Ovariectomy, Sex Characteristics, Angiotensins metabolism, Colon metabolism, Colon physiopathology, Estrogens deficiency, Menopause, Receptors, Dopamine metabolism
- Abstract
The physiopathological mechanisms that regulate menopausal and sex differences in colonic transit, inflammatory processes, and efficacy of treatments have not been clarified. The dopaminergic system and renin-angiotensin system coexist in the gut and regulate different processes such as motility, absorption/secretion, and inflammation. We investigated the changes in expression of major angiotensin and dopamine receptors in the colon of male, female, and ovariectomized female mice. Possible interaction between both systems was investigated using male and female mice deficient (ko) for major angiotensin and dopamine receptors. In wild-type mice, colonic tissue from females showed lower angiotensin type 1/angiotensin type 2 ratio (an index of pro-inflammatory/anti-inflammatory renin-angiotensin system balance), lower dopamine D1 and D2 receptor expression, and lower levels of pro-inflammatory and pro-oxidative markers relative to males. Interestingly, ovariectomy increased the expression of pro-inflammatory angiotensin type 1 receptor expression and decreased anti-inflammatory angiotensin type 2 receptor expression, increased D1 and D2 receptor expression, and increased the levels of pro-inflammatory and pro-oxidative markers. Ovariectomy-induced changes were blocked by estrogen replacement. The present results suggest a mutual regulation between colonic angiotensin and dopamine receptors and sex differences in this mutual regulation. Estrogen regulates changes in both angiotensin and dopamine receptor expression, which may be involved in sex- and surgical menopause-related effects on gut motility, permeability, and vulnerability to inflammatory processes., (© The Author(s) 2020. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
7. Ambulatory Treatments for RAAS Inhibitor-Related Hyperkalemia and the 1-Year Risk of Recurrence.
- Author
-
Hundemer GL, Talarico R, Tangri N, Leon SJ, Bota SE, Rhodes E, Knoll GA, and Sood MM
- Subjects
- Aged, Aged, 80 and over, Ambulatory Care, Cohort Studies, Female, Humans, Male, Recurrence, Retrospective Studies, Risk Assessment, Time Factors, Angiotensins antagonists & inhibitors, Hyperkalemia chemically induced, Hyperkalemia therapy, Mineralocorticoid Receptor Antagonists therapeutic use, Renin antagonists & inhibitors
- Abstract
Background and Objective: The optimal ambulatory management of renin-angiotensin-aldosterone system inhibitor (RAASi)-related hyperkalemia to reduce the risk of recurrence is unknown. We examined the risk of hyperkalemia recurrence on the basis of outpatient pharmacologic changes following an episode of RAASi-related hyperkalemia., Design: We performed a population-based, retrospective cohort study of older adults ( n =49,571; mean age 79 years) who developed hyperkalemia (potassium ≥5.3 mEq/L) while on a RAASi and were grouped as follows: no intervention, RAASi discontinuation, RAASi dose decrease, new diuretic, diuretic dose increase, or sodium polystyrene sulfonate within 30 days. The primary outcome was hyperkalemia recurrence, with secondary outcomes of cardiovascular events and all-cause mortality within 1 year., Results: Among patients who received a pharmacologic intervention (23% of the cohort), RAASi discontinuation was the most commonly prescribed strategy (74%), followed by RAASi decrease (15%), diuretic increase (7%), new diuretic (3%), and sodium polystyrene sulfonate (1%). A total of 16,977 (34%) recurrent hyperkalemia events occurred within 1 year. Compared with no intervention (35%, referent), the cumulative incidence of recurrent hyperkalemia was lower with RAASi discontinuation (29%; hazard ratio, 0.82; 95% confidence interval, 0.78 to 0.85), whereas there was no difference with RAASi dose decrease (36%; hazard ratio, 0.94; 95% confidence interval, 0.86 to 1.02), new diuretic (32%; hazard ratio, 0.95; 95% confidence interval, 0.78 to 1.17), or diuretic increase (38%; hazard ratio, 0.99; 95% confidence interval, 0.87 to 1.12) and a higher incidence with sodium polystyrene sulfonate (55%; hazard ratio, 1.30; 95% confidence interval, 1.04 to 1.63). RAASi discontinuation was not associated with a higher risk of 1-year cardiovascular events (hazard ratio, 0.96; 95% confidence interval, 0.91 to 1.02) or all-cause mortality (hazard ratio, 1.05; 95% confidence interval, 0.96 to 1.15) compared with no intervention., Conclusions: Among older adults with RAASi-related hyperkalemia, RAASi discontinuation is associated with the lowest risk of recurrent hyperkalemia, with no apparent increase in short-term risks for cardiovascular events or all-cause mortality., (Copyright © 2021 by the American Society of Nephrology.)
- Published
- 2021
- Full Text
- View/download PDF
8. Angiotensin-(3-4) normalizes blood pressure, decreases Na + and energy intake, but preserves urinary Na + excretion in overweight hypertensive rats.
- Author
-
Luzes R, Crisóstomo T, Silva PA, Iack R, de Abreu VG, Francischetti EA, and Vieyra A
- Subjects
- Animals, Hypertension complications, Hypertension physiopathology, Hypertension urine, Male, Overweight complications, Overweight physiopathology, Overweight urine, Rats, Rats, Wistar, Sodium metabolism, Sodium urine, Angiotensins therapeutic use, Blood Pressure drug effects, Energy Intake drug effects, Hypertension drug therapy, Overweight drug therapy, Peptide Fragments therapeutic use
- Abstract
Hypertension, one of the most common and severe comorbidities of obesity and overweight, is a worldwide epidemic affecting over 30% of the population. We induced overweight in young male rats (aged 58 days) by exposure to a hypercaloric high lipid (HL) diet in which 70% of the calories originated from fat. The HL diet also contained 33 or 57% higher Na
+ than the control (CTR) diet. Over the following weeks the HL rats gradually became overweight (490 ± 12 g vs 427 ± 7 g in the CTR group after 15 weeks) with high visceral fat. They developed elevated systolic blood pressure (SBP) (141 ± 1.9 mmHg), which was fully restored to CTR values (128 ± 1.1 mmHg) by oral administration of Ang-(3-4) (Val-Tyr), the shortest renin-angiotensin-derived peptide. The overweight rats had lower plasma Na+ concentration that augmented to CTR values by Ang-(3-4) treatment. Na+ ingestion was depressed by 40% as result of the Ang-(3-4) treatment, whereas the urinary excretion of Na+ (UNa V) remained unmodified. The preservation of UNa V after Ang-(3-4) treatment - despite the sharp decrease in the dietary Na+ intake - can be ascribed to the normalization of renal type 1 angiotensin II receptors and Na+ -transporting ATPases, both up-regulated in overweight rats. These renal effects complete a counterregulatory action on elevated renin-angiotensin activity that allows the high SBP to be normalized and body Na+ homeostasis to be restored concomitantly in overweight rats., (Copyright © 2020 Elsevier B.V. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
9. An Angiotensin-Responsive Connection from the Lamina Terminalis to the Paraventricular Nucleus of the Hypothalamus Evokes Vasopressin Secretion to Increase Blood Pressure in Mice.
- Author
-
Frazier CJ, Harden SW, Alleyne AR, Mohammed M, Sheng W, Smith JA, Elsaafien K, Spector EA, Johnson DN, Scott KA, Krause EG, and de Kloet AD
- Subjects
- Animals, Basal Nucleus of Meynert drug effects, Basal Nucleus of Meynert metabolism, Drinking drug effects, Genes, fos drug effects, Glutamic Acid physiology, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Optogenetics, Receptor, Angiotensin, Type 1 drug effects, Receptors, Vasopressin drug effects, Sodium, Dietary, Angiotensins pharmacology, Arginine Vasopressin metabolism, Blood Pressure drug effects, Hypothalamus drug effects, Neural Pathways drug effects, Paraventricular Hypothalamic Nucleus drug effects, Vasoconstrictor Agents pharmacology
- Abstract
Blood pressure is controlled by endocrine, autonomic, and behavioral responses that maintain blood volume and perfusion pressure at levels optimal for survival. Although it is clear that central angiotensin type 1a receptors (AT1aR; encoded by the Agtr1a gene) influence these processes, the neuronal circuits mediating these effects are incompletely understood. The present studies characterize the structure and function of AT1aR neurons in the lamina terminalis (containing the median preoptic nucleus and organum vasculosum of the lamina terminalis), thereby evaluating their roles in blood pressure control. Using male Agtr1a -Cre mice, neuroanatomical studies reveal that AT1aR neurons in the area are largely glutamatergic and send projections to the paraventricular nucleus of the hypothalamus (PVN) that appear to synapse onto vasopressin-synthesizing neurons. To evaluate the functionality of these lamina terminalis AT1aR neurons, we virally delivered light-sensitive opsins and then optogenetically excited or inhibited the neurons while evaluating cardiovascular parameters or fluid intake. Optogenetic excitation robustly elevated blood pressure, water intake, and sodium intake, while optogenetic inhibition produced the opposite effects. Intriguingly, optogenetic excitation of these AT1aR neurons of the lamina terminalis also resulted in Fos induction in vasopressin neurons within the PVN and supraoptic nucleus. Further, within the PVN, selective optogenetic stimulation of afferents that arise from these lamina terminalis AT1aR neurons induced glutamate release onto magnocellular neurons and was sufficient to increase blood pressure. These cardiovascular effects were attenuated by systemic pretreatment with a vasopressin-1a-receptor antagonist. Collectively, these data indicate that excitation of lamina terminalis AT1aR neurons induces neuroendocrine and behavioral responses that increase blood pressure. SIGNIFICANCE STATEMENT Hypertension is a widespread health problem and risk factor for cardiovascular disease. Although treatments exist, a substantial percentage of patients suffer from "drug-resistant" hypertension, a condition associated with increased activation of brain angiotensin receptors, enhanced sympathetic nervous system activity, and elevated vasopressin levels. The present study highlights a role for angiotensin Type 1a receptor expressing neurons located within the lamina terminalis in regulating endocrine and behavioral responses that are involved in maintaining cardiovascular homeostasis. More specifically, data presented here reveal functional excitatory connections between angiotensin-sensitive neurons in the lamina terminals and vasopressin neurons in the paraventricular nucleus of the hypothalamus, and further indicate that activation of this circuit raises blood pressure. These neurons may be a promising target for antihypertensive therapeutics., (Copyright © 2021 the authors.)
- Published
- 2021
- Full Text
- View/download PDF
10. The relationship of plasma renin, angiotensin, and aldosterone levels to blood pressure variability and target organ damage in children with essential hypertension.
- Author
-
Liu Y, Lin Y, Zhang MM, Li XH, Liu YY, Zhao J, and Shi L
- Subjects
- Adolescent, Age Factors, Biomarkers blood, Child, Essential Hypertension blood, Essential Hypertension diagnosis, Essential Hypertension physiopathology, Female, Humans, Hypertrophy, Left Ventricular blood, Hypertrophy, Left Ventricular diagnosis, Hypertrophy, Left Ventricular physiopathology, Kidney Diseases blood, Kidney Diseases diagnosis, Kidney Diseases physiopathology, Male, Risk Factors, Aldosterone blood, Angiotensins blood, Blood Pressure, Essential Hypertension complications, Hypertrophy, Left Ventricular etiology, Kidney Diseases etiology, Renin blood, Renin-Angiotensin System
- Abstract
Background: To investigate the relationships of plasma renin, angiotensin, and aldosterone levels to blood pressure variability and target organ damage in children with essential hypertension., Methods: A case-control study was conducted on 132 children diagnosed with essential hypertension (103 males and 29 females with the mean age of 11.8 ± 2.4 years). The plasma RAAS levels were measured using the enhanced chemiluminescence method, the ambulatory blood pressure was monitored for 24 h, and then the average real variability (ARV) was calculated. Data on indicators were used for assessing cardiac and renal damages. The correlations of plasma renin, angiotensin, and aldosterone (RAAS) levels to blood pressure variability (BPV) and target organ damage (TOD) were studied. A comparison between the groups was conducted using SPSS 20., Results: Among the 132 children, 55 cases had target organ damage. The 24-h ARV and the daytime ARV of the systolic blood pressure of the high angiotensin II (AT II) group was significantly higher than that of the normal AT II group (t = 2.175, P = 0.031; t = 2.672, P = 0.009). Plasma AT II and aldosterone levels were significantly associated with the left ventricular mass index (r = 0.329, P = 0.0001; r = 0.175, P = 0.045). Linear regression analysis showed that AT II [β ± s.e. = 0.025 ± 0.006, 95% CI (0.013-0.038), P = 0.0001] and aldosterone [β ± s.e. = 0.021 ± 0.007, 95% CI (0.008-0.034), P = 0.002] were risk factors for LVH., Conclusions: The AT II level in children with essential hypertension affected the variability of the 24-h and the daytime SBP. Plasma AT II and aldosterone levels were associated with cardiac damage. Results from this study indicated that AT II and aldosterone are risk factors for LVH in childhood hypertension and are of great significance for improving the clinical prognosis of pediatric patients with hypertension.
- Published
- 2020
- Full Text
- View/download PDF
11. Association between angiotensin blockade and COVID-19 severity in Hong Kong.
- Author
-
Cheung KS, Hung IFN, and Leung WK
- Subjects
- Betacoronavirus, COVID-19, Coronavirus Infections, Hong Kong, Humans, Pandemics, Pneumonia, Viral, SARS-CoV-2, Angiotensins, Renin-Angiotensin System
- Abstract
Competing Interests: Competing interests: None declared.
- Published
- 2020
- Full Text
- View/download PDF
12. Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial.
- Author
-
Wachter R, Shah SJ, Cowie MR, Szecsödy P, Shi V, Ibram G, Zhao Z, Gong J, Klebs S, and Pieske B
- Subjects
- Humans, Prospective Studies, Quality of Life, Receptors, Angiotensin, Renin-Angiotensin System, Stroke Volume, Angiotensins, Neprilysin
- Abstract
Aims: Although the effect of the angiotensin receptor blocker neprilysin inhibitor (ARNI) sacubitril/valsartan on heart failure (HF) hospitalizations and cardiovascular death has been evaluated, its effects on functional capacity in patients with HF and ejection fraction (EF) >40% has yet to be determined. In addition, no prior studies have compared sacubitril/valsartan with angiotensin-converting enzyme inhibitor therapy. We sought to compare the effect of ARNI to background-medication-based individualized comparators (BMICs) on N-terminal pro-B-type natriuretic peptide (NT-proBNP), functional capacity [6 min walk distance (6MWD)], symptoms, and quality of life [Kansas City Cardiomyopathy Questionnaire (KCCQ)] in patients with HF and EF >40% in a randomized clinical trial., Methods: PARALLAX is a prospective, randomized, controlled, double-blind multicentre clinical trial in patients with chronic symptomatic HF with EF >40%, New York Heart Association (NYHA) class II-IV symptoms, elevated natriuretic peptides, and evidence of structural heart disease. Eligible patients are randomized to sacubitril/valsartan vs. BMIC for cardiovascular and related co-morbidities. BMIC includes (i) enalapril, (ii) valsartan, and (iii) placebo depending on the type of medical therapy prior to enrolment. The primary endpoints are the change in plasma NT-proBNP concentration from baseline to 12 weeks and the change from baseline in 6MWD distance at 24 weeks. The secondary endpoints assess quality of life and symptom burden., Conclusions: PARALLAX will determine if sacubitril/valsartan compared with standard medical therapy for co-morbidities improves NT-proBNP levels, exercise capacity, quality of life, and symptom burden in HF patients with EF >40%., (© 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.)
- Published
- 2020
- Full Text
- View/download PDF
13. Role of the renin-angiotensin system in kidney development and programming of adult blood pressure.
- Author
-
Almeida LF, Tofteng SS, Madsen K, and Jensen BL
- Subjects
- Animals, Blood Pressure, Humans, Hypertension genetics, Hypertension metabolism, Hypertension physiopathology, Kidney metabolism, Vascular Endothelial Growth Factor A genetics, Vascular Endothelial Growth Factor A metabolism, Angiotensins metabolism, Kidney growth & development, Renin metabolism, Renin-Angiotensin System
- Abstract
Adverse events during fetal life such as insufficient protein intake or elevated transfer of glucocorticoid to the fetus may impact cardiovascular and metabolic health later in adult life and are associated with increased incidence of type 2 diabetes, ischemic heart disease and hypertension. Several adverse factors converge and suppress the fetal renin-angiotensin-aldosterone system (RAAS). The aim of this review is to summarize data on the significance of RAAS for kidney development and adult hypertension. Genetic inactivation of RAAS in rodents at any step from angiotensinogen to angiotensin II (ANGII) type 1 receptor (AT1) receptors or pharmacologic inhibition leads to complex developmental injury to the kidneys that has also been observed in human case reports. Deletion of the 'protective' arm of RAAS, angiotensin converting enzyme (ACE) 2 (ACE-2) and G-protein coupled receptor for Angiotensin 1-7 (Mas) receptor does not reproduce the AT1 phenotype. The changes comprise fewer glomeruli, thinner cortex, dilated tubules, thicker arterioles and arteries, lack of vascular bundles, papillary atrophy, shorter capillary length and volume in cortex and medulla. Altered activity of systemic and local regulators of fetal-perinatal RAAS such as vitamin D and cyclooxygenase (COX)/prostaglandins are associated with similar injuries. ANGII-AT1 interaction drives podocyte and epithelial cell formation of vascular growth factors, notably vascular endothelial growth factor (VEGF) and angiopoietins (Angpts), which support late stages of glomerular and cortical capillary growth and medullary vascular bundle formation and patterning. RAAS-induced injury is associated with lower glomerular filtration rate (GFR), lower renal plasma flow, kidney fibrosis, up-regulation of sodium transporters, impaired sodium excretion and salt-sensitive hypertension. The renal component and salt sensitivity of programmed hypertension may impact dietary counseling and choice of pharmacological intervention to treat hypertension., (© 2020 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.)
- Published
- 2020
- Full Text
- View/download PDF
14. Mast cell peptidases (carboxypeptidase A and chymase)-mediated hydrolysis of human angiotensin-(1-12) substrate.
- Author
-
Ahmad S, Wright KN, Sun X, Groban L, and Ferrario CM
- Subjects
- Amino Acid Sequence, Angiotensin I metabolism, Animals, Carboxypeptidases A genetics, Chymases genetics, Humans, Hydrolysis, Mast Cells metabolism, Myocardium metabolism, Peptide Fragments metabolism, Substrate Specificity, alpha 1-Antitrypsin, Angiotensinogen metabolism, Angiotensins metabolism, Carboxypeptidases A metabolism, Chymases metabolism, Recombinant Proteins metabolism
- Abstract
Angiotensin processing peptidases (carboxypeptidase A (CPA) and chymase) are stored in cardiac mast cell (MC) secretory granules in large quantity and are co-released into the extracellular environment after activation/degranulation. In the human heart, chymase is primarily responsible for angiotensin II (Ang II) generation from the alternate substrate angiotensin-(1-12) (Ang-(1-12)). We investigated the individual and combined hydrolytic specificity of CPA and chymase enzymes (1:1 and 1:⅓ ratio) in the processing of the human Ang-(1-12) (hAng-(1-12)) substrate. To determine the K
m and Vmax , the CPA and recombinant human chymase (rhChymase) enzymes were incubated with increasing concentrations of hAng-(1-12) substrate (0-300 μM). We found that CPA alone sequentially metabolized hAng-(1-12) substrate into angiotensin-(1-9) (Ang-(1-9), 53%), Ang II (22%) and angiotensin-(1-7) (Ang-(1-7), 11%) during a 15 min incubation. In the presence of rhChymase alone,125 I-hAng-(1-12) was directly metabolized into Ang II (89%) and no further hydrolysis of Ang II was detected. In the presence of both CPA + rhChymase enzymes (1:1 or 1:⅓ ratio), the amount of Ang II formation from125 I-hAng-(1-12) within a 5 min incubation period were 68% or 65%, respectively. In the presence of both (CPA + rhChymase), small amounts of Ang-(1-9) and Ang-(1-7) were generated from125 I-hAng-(1-12). The Km and Vmax values were 150 ± 5 μM and 384 ± 23 nM/min/mg of CPA and 40 ± 9 μM and 116 ± 20 nM/min/mg of rhChymase. The catalytic efficiency (Vmax /Km ratio) was higher for rhChymase/hAng-(1-12) compared to CPA/hAng-(1-12). Compared to CPA, chymase has a much higher affinity to hydrolyze the hAng-(1-12) substrate directly into Ang II. In addition, Ang II and Ang-(1-7) are the end products of chymase and CPA, respectively. Overall, our findings suggest that the Ang II generation from hAng-(1-12) is primarily mediated by chymase rather than CPA., (Copyright © 2019 Elsevier Inc. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
15. Angs (Angiotensins) of the Alternative Renin-Angiotensin System Predict Outcome in Patients With Heart Failure and Preserved Ejection Fraction.
- Author
-
Binder C, Poglitsch M, Agibetov A, Duca F, Zotter-Tufaro C, Nitsche C, Aschauer S, Kammerlander AA, Oeztuerk B, Hengstenberg C, Mascherbauer J, and Bonderman D
- Subjects
- Academic Medical Centers, Aged, Austria, Cohort Studies, Female, Heart Failure blood, Heart Failure mortality, Heart Failure physiopathology, Humans, Kaplan-Meier Estimate, Male, Multivariate Analysis, Peptidyl-Dipeptidase A metabolism, Predictive Value of Tests, Prognosis, Proportional Hazards Models, Prospective Studies, Registries, Risk Assessment, Stroke Volume drug effects, Survival Analysis, Angiotensin-Converting Enzyme Inhibitors administration & dosage, Angiotensins metabolism, Cause of Death, Heart Failure drug therapy, Renin-Angiotensin System drug effects, Stroke Volume physiology
- Abstract
The renin-angiotensin system plays an important role in the development and progression of heart failure (HF). In addition to the classical renin-angiotensin pathway, an alternative pathway produces Angs (angiotensins), which counteract the negative effects of Ang II. We hypothesized that Ang profiling could provide insights into the pathogenesis and prognosis of HF with preserved ejection fraction. We aimed to investigate the effects of Angs on outcome in HF with preserved ejection fraction. Consecutive patients were included into a prospective single-center registry. Clinical, laboratory, and imaging parameters were assessed and serum samples were taken at baseline and measured by mass spectroscopy. Serum equilibrium levels were analyzed in regard to the combined clinical end point of cardiovascular death or HF hospitalization. In total, 155 patients were included during a median follow-up time of 22.5 (interquartile range, 4.0-61.0) months, 52 individuals (34%) reached the combined end point. We identified higher levels of Ang 1-7 and Ang 1-5 as predictors for poor outcome. After adjusting for potential confounding factors, Ang 1-5 remained predictive for poor outcome. In addition to Ang 1-7 and Ang 1-5, the novel ACE (angiotensin-converting enzyme) independent Ang composite marker [Ang 1-7+Ang 1-5] was shown to predict adverse events. We conclude that Angs of the alternative renin-angiotensin system seem to play a role in HF with preserved ejection fraction and are linked to outcome in patients with HF and preserved ejection fraction. Ang 1-5 and the alternative renin-angiotensin system composite marker [Ang 1-7+Ang 1-5] are independent predictors of outcome.
- Published
- 2019
- Full Text
- View/download PDF
16. A microanalytical capillary electrophoresis mass spectrometry assay for quantifying angiotensin peptides in the brain.
- Author
-
Lombard-Banek C, Yu Z, Swiercz AP, Marvar PJ, and Nemes P
- Subjects
- Animals, Male, Mice, Mice, Inbred C57BL, Proof of Concept Study, Angiotensins metabolism, Brain metabolism, Electrophoresis, Capillary methods, Spectrometry, Mass, Electrospray Ionization methods
- Abstract
The renin-angiotensin system (RAS) of the brain produces a series of biologically active angiotensinogen-derived peptides involved in physiological homeostasis and pathophysiology of disease. Despite significant research efforts to date, a comprehensive understanding of brain RAS physiology is lacking. A significant challenge has been the limited set of bioanalytical assays capable of detecting angiotensin (Ang) peptides at physiologically low concentrations (2-15 fmol/g of wet tissue) and sufficient chemical specificity for unambiguous molecular identifications. Additionally, a complex brain anatomy calls for microanalysis of specific tissue regions, thus further taxing sensitivity requirements for identification and quantification in studies of the RAS. To fill this technology gap, we here developed a microanalytical assay by coupling a laboratory-built capillary electrophoresis (CE) nano-electrospray ionization (nano-ESI) platform to a high-resolution mass spectrometer (HRMS). Using parallel reaction monitoring, we demonstrated that this technology achieved confident identification and quantification of the Ang peptides at approx. 5 amol to 300 zmol sensitivity. This microanalytical assay revealed differential Ang peptide profiles between tissues that were micro-sampled from the subfornical organ and the paraventricular nucleus of the hypothalamus, important brain regions involved in thirst and water homeostasis and neuroendocrine regulation to stress. Microanalytical CE-nano-ESI-HRMS extends the analytical toolbox of neuroscience to help better understand the RAS.
- Published
- 2019
- Full Text
- View/download PDF
17. Plasma and tissue angiotensin-converting enzyme 2 activity and plasma equilibrium concentrations of angiotensin peptides in dogs with heart disease.
- Author
-
Larouche-Lebel É, Loughran KA, Oyama MA, Solter PF, Laughlin DS, Sánchez MD, Assenmacher CA, Fox PR, and Fries RC
- Subjects
- Angiotensin-Converting Enzyme 2, Animals, Case-Control Studies, Dogs, Female, Heart Diseases blood, Heart Diseases enzymology, Heart Failure blood, Heart Failure enzymology, Heart Failure veterinary, Immunohistochemistry, Kidney enzymology, Male, Myocardium enzymology, Peptides blood, Peptidyl-Dipeptidase A analysis, Renin-Angiotensin System, Angiotensins blood, Heart Diseases veterinary, Peptidyl-Dipeptidase A blood
- Abstract
Background: Angiotensin-converting enzyme 2 (ACE2) is a homologue of angiotensin-converting enzyme (ACE) and produces angiotensin peptides (APs), such as angiotensin 1-9 and 1-7 that are vasodilatory and natriuretic, and act to counterbalance angiotensin II., Hypothesis: Evidence of ACE2 can be found in tissues and plasma of dogs. Equilibrium concentrations of renin angiotensin aldosterone system (RAAS) APs differ in dogs with heart disease compared to healthy dogs and recombinant human ACE2 (rhACE2) alters relative concentrations of APs., Animals: Forty-nine dogs with and 34 dogs without heart disease., Methods: Immunohistochemistry and assays for tissue and plasma ACE2 activity and equilibrium concentrations of plasma RAAS APs were performed., Results: Immunolabeling for ACE2 was present in kidney and myocardial tissue. Median plasma ACE2 activity was significantly increased in dogs with congestive heart failure (CHF; 6.9 mU/mg; interquartile range [IQR], 5.1-12.1) as compared to control (2.2 mU/mg; IQR, 1.8-3.0; P = .0003). Plasma equilibrium analysis of RAAS APs identified significant increases in the median concentrations of beneficial APs, such as angiotensin 1-7, in dogs with CHF (486.7 pg/mL; IQR, 214.2-1168) as compared to those with preclinical disease (41.0 pg/mL; IQR, 27.4-45.1; P < .0001) or control (11.4 pg/mL; IQR, 7.1-25.3; P = .01). Incubation of plasma samples from dogs with CHF with rhACE2 increased beneficial APs, such as angiotensin 1-9 (preincubation, 10.3 pg/mL; IQR, 4.4-37.2; postincubation, 2431 pg/mL; IQR, 1355-3037; P = .02), while simultaneously decreasing maladaptive APs, such as angiotensin II (preincubation, 53.4 pg/mL; IQR, 28.6-226.4; postincubation, 2.4 pg/mL; IQR, 0.50-5.8; P = .02)., Conclusions and Clinical Importance: Recognition of the ACE2 system expands the conventional view of the RAAS in the dog and represents an important potential therapeutic target., (© 2019 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.)
- Published
- 2019
- Full Text
- View/download PDF
18. Could angiotensin-modulating drugs be relevant for the treatment of Trypanosoma cruzi infection? A systematic review of preclinical and clinical evidence.
- Author
-
Souza-Silva TG, Diniz LF, Lia Mazzeti A, Mendonça AAS, Gonçalves RV, and Novaes RD
- Subjects
- Animals, CD8-Positive T-Lymphocytes immunology, Captopril therapeutic use, Chagas Cardiomyopathy drug therapy, Chagas Disease immunology, Clinical Studies as Topic, Cytokines immunology, Drug Evaluation, Preclinical, Enalapril therapeutic use, Humans, Losartan therapeutic use, Mice, Trypanosoma cruzi drug effects, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Angiotensins antagonists & inhibitors, Chagas Disease drug therapy
- Abstract
Although leucocytes are targets of renin-angiotensin system (RAS) effector molecules and RAS-modulating drugs exert immunomodulatory effects, their impact on Trypanosoma cruzi infection remains poorly understood. By using the framework of a systematic review, we integrated the preclinical and clinical evidence to investigate the relevance of angiotensin-inhibiting drugs on T. cruzi infections. From a comprehensive and structured search in biomedical databases, only original studies were analysed. In preclinical and clinical studies, captopril, enalapril and losartan were RAS-modulating drugs used. The main in vitro findings indicated that these drugs increased parasite uptake per host cells, IL-12 expression by infected dendritic cells and IFN-γ by T lymphocytes, in addition to attenuating IL-10 and IL-17 production by CD8 + T cells. In animal models, reduced parasitaemia, tissue parasitism, leucocytes infiltration and mortality were often observed in T. cruzi-infected animals receiving RAS-modulating drugs. In patients with Chagas' disease, these drugs exerted a controversial impact on cytokine and hormone levels, and a limited effect on cardiovascular function. Considering a detailed evaluation of reporting and methodological quality, the current preclinical and clinical evidence is at high risk of bias, and we hope that our critical analysis will be useful in mitigating the risk of bias in further studies.
- Published
- 2019
- Full Text
- View/download PDF
19. Effect of Prolonged Infusion of Alamandine on Cardiovascular Parameters and Cardiac ACE2 Expression in a Rat Model of Renovascular Hypertension.
- Author
-
Hekmat AS, Zare N, Moravej A, Meshkibaf MH, and Javanmardi K
- Subjects
- Angiotensin-Converting Enzyme 2, Angiotensins administration & dosage, Animals, Blood Pressure drug effects, Cardiovascular System drug effects, Cardiovascular System physiopathology, Disease Models, Animal, Hypertension, Renovascular enzymology, Hypertension, Renovascular physiopathology, Hypertrophy pathology, Kidney drug effects, Kidney metabolism, Male, Myocardium enzymology, Peptidyl-Dipeptidase A metabolism, RNA, Messenger biosynthesis, RNA, Messenger genetics, Random Allocation, Rats, Rats, Sprague-Dawley, Angiotensins pharmacology, Antihypertensive Agents administration & dosage, Hypertension, Renovascular drug therapy, Oligopeptides administration & dosage, Peptidyl-Dipeptidase A biosynthesis
- Abstract
Alamandine is a new member of the angiotensin family. Here, we studied the mRNA and protein expression of cardiac angiotensin-converting enzyme 2 (ACE2) in the chronic phase of a rat model of 2-kidney, 1-clip hypertension (2K1C), and the effects of 2-week alamandine infusion on blood pressure, cardiac indices, and ACE2 mRNA and protein expression in the hearts. The rats were subjected to to sham-operation or placement of plexiglass clips around the left renal artery. Alamandine, at a dose of 600 µg/kg/d, was administered for 2 weeks via an osmotic mini-pump. At 18 weeks, after induction of hypertension, blood pressure and cardiac indices of contractility were measured using a Powerlab Physiograph system. The ACE2 mRNA and protein levels were determined using real time-PCR and Western blotting, respectively. In the hypertensive rats, alamandine caused a significant decrease in systolic blood pressure (p < 0.001), diastolic blood pressure (p < 0.001), left ventricular end-diastolic pressure (p < 0.001) and, left ventricular systolic pressure (p < 0.001) and increase in the maximum rate of pressure change in the left ventricle (dP/dt(max)) (p < 0.05). Also, the ACE2 mRNA expression in the heart increased in the hypertensive rats compared to the normotensive rats (p < 0.05), and alamandine restored this to normal values, although these changes were only seen at the mRNA and not the protein level. Histological analysis of cardiac tissue confirmed that alamandine decreased cardiac fibrosis and hypertrophy in 2K1C hypertensive rats. Our results indicate that alamandine, which acts as a depressor arm of the renin-angiotensin system, could be developed for treating hypertension.
- Published
- 2019
- Full Text
- View/download PDF
20. Role of the Angiotensin Pathway and its Target Therapy in Epilepsy Management.
- Author
-
Krasniqi S and Daci A
- Subjects
- Angiotensin II Type 1 Receptor Blockers pharmacology, Angiotensin II Type 1 Receptor Blockers therapeutic use, Animals, Anticonvulsants pharmacology, Astrocytes drug effects, Astrocytes metabolism, Biomarkers, Blood-Brain Barrier drug effects, Blood-Brain Barrier metabolism, Drug Discovery, Epilepsy etiology, Humans, Microglia drug effects, Microglia metabolism, Pharmacogenetics methods, Precision Medicine methods, Receptor, Angiotensin, Type 1 metabolism, ras Proteins antagonists & inhibitors, ras Proteins genetics, ras Proteins metabolism, Angiotensins metabolism, Anticonvulsants therapeutic use, Epilepsy drug therapy, Epilepsy metabolism, Molecular Targeted Therapy, Renin-Angiotensin System drug effects, Signal Transduction drug effects
- Abstract
Despite extensive research on epileptogenesis, there is still a need to investigate new pathways and targeted therapeutic approaches in this complex process. Inflammation, oxidative stress, neurotoxicity, neural cell death, gliosis, and blood⁻brain barrier (BBB) dysfunction are the most common causes of epileptogenesis. Moreover, the renin⁻angiotensin system (RAS) affects the brain's physiological and pathological conditions, including epilepsy and its consequences. While there are a variety of available pharmacotherapeutic approaches, information on new pathways is in high demand and the achievement of treatment goals is greatly desired. Therefore, targeting the RAS presents an interesting opportunity to better understand this process. This has been supported by preclinical studies, primarily based on RAS enzyme, receptor-inhibition, and selective agonists, which are characterized by pleiotropic properties. Although there are some antiepileptic drugs (AEDs) that interfere with RAS, the main targeted therapy of this pathway contributes in synergy with AEDs. However, the RAS-targeted treatment alone, or in combination with AEDs, requires clinical studies to contribute to, and clarify, the evidence on epilepsy management. There is also a genetic association between RAS and epilepsy, and an involvement of pharmacogenetics in RAS, so there are possibilities for the development of new diagnostic and personalized treatments for epilepsy., Competing Interests: The authors declare no conflicts of interest.
- Published
- 2019
- Full Text
- View/download PDF
21. Further studies needed before using renin-angiotensin-aldosterone system blockade for atrial fibrillation prevention in hypertrophic cardiomyopathy.
- Author
-
Ramchand J, Sampaio Rodrigues T, Yudi MB, and Burrell LM
- Subjects
- Aldosterone, Atrial Fibrillation, Humans, Renin, Renin-Angiotensin System, Angiotensins, Cardiomyopathy, Hypertrophic
- Abstract
Competing Interests: Competing interests: None declared.
- Published
- 2018
- Full Text
- View/download PDF
22. Angiotensin-(1-9) reduces cardiovascular and renal inflammation in experimental renin-independent hypertension.
- Author
-
Gonzalez L, Novoa U, Moya J, Gabrielli L, Jalil JE, García L, Chiong M, Lavandero S, and Ocaranza MP
- Subjects
- Actins genetics, Actins metabolism, Animals, Aorta cytology, Aorta drug effects, Aorta pathology, Desoxycorticosterone toxicity, Hypertension drug therapy, Inflammation drug therapy, Kidney Diseases drug therapy, Male, Rats, Rats, Sprague-Dawley, Angiotensins pharmacology, Hypertension chemically induced, Inflammation chemically induced, Kidney Diseases chemically induced, Renin metabolism
- Abstract
Hypertension-induced cardiovascular and renal damage can be mediated by activation of the renin-angiotensin-aldosterone system. There are different factors beyond renin-angiotensin-aldosterone system involved in hypertension and renal damage. Inflammation has emerged as an important mediator of hypertension and cardiovascular and kidney damage. Angiotensin-(1-9), a peptide of the renin-angiotensin system, counter-regulates both the physiological and pathological actions of angiotensin II. Recent data has shown that angiotensin-(1-9) protects the heart and blood vessels from adverse cardiovascular remodeling in experimental models of hypertension and/or heart failure and reduces cardiac fibrosis in stroke-prone, spontaneously hypertensive rats. These effects are mediated by the angiotensin II type 2 receptor (AT2R). However, it remains unknown whether angiotensin-(1-9) also has an anti-inflammatory effect. In the present study, we investigate whether angiotensin-(1-9) reduces inflammation and fibrosis in the heart, arteries, and kidney in a DOCA-salt hypertensive model and explore the mechanisms underlying the amelioration of end-organ damage. DOCA-salt hypertensive rats received: a) vehicle, b) angiotensin-(1-9), c) PD123319 (AT2R blocker), d) angiotensin-(1-9) plus A779 (a Mas receptor blocker) or e) angiotensin-(1-9) plus PD123319, and sham rats were used as a control. Our results showed that angiotensin-(1-9) decreased hypertension and increased vasodilation in DOCA-salt hypertensive rats. These actions were partially inhibited by PD123319. Moreover, angiotensin-(1-9) decreased diuresis, fibrosis, and inflammation. These beneficial effects were not mediated by Mas or AT2R blockers. We concluded that angiotensin-(1-9) protects against volume overload-induced hypertensive cardiovascular and kidney damage by decreasing inflammation in the heart, aortic wall, and kidney, through mechanisms independent of the Mas or AT2R., (Copyright © 2018 Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
23. Renin-Angiotensin-Aldosterone Profiles in Pregnant Women With Chronic Hypertension.
- Author
-
Malha L, Sison CP, Helseth G, Sealey JE, and August P
- Subjects
- Adolescent, Adult, Blood Pressure drug effects, Blood Pressure physiology, Chronic Disease, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypertension drug therapy, Hypertension physiopathology, Middle Aged, Pregnancy, Pregnancy Complications, Cardiovascular drug therapy, Pregnancy Complications, Cardiovascular physiopathology, Prospective Studies, Young Adult, Aldosterone metabolism, Angiotensins metabolism, Calcium Carbonate therapeutic use, Hypertension metabolism, Pregnancy Complications, Cardiovascular metabolism, Renin metabolism, Renin-Angiotensin System physiology
- Abstract
Pregnant women with chronic hypertension are at risk for increased blood pressure and superimposed preeclampsia (SPE) in late pregnancy. Alterations in the renin-aldosterone system are a feature of normal pregnancy; however, their role in chronic hypertension with and without SPE is less clear. We performed a prospective, longitudinal trial of 108 women with chronic hypertension and measured plasma renin activity (PRA), 24-hour urine sodium, urine potassium, and urine aldosterone (Ualdo) at 12, 20, 28, and 36 weeks and postpartum. SPE developed in 34% of pregnancies. PRA was lower in women who developed SPE at weeks 28 (5.99 versus 6.22 ng/mL per hour; P <0.001) and 36 (5.71 versus 7.74 ng/mL per hour; P =0.002). Ualdo was lower in women with SPE compared with those without SPE at 28 weeks (59.6 versus 81.3 μg/d; P =0.039). Mean arterial pressure was inversely related to both PRA ( r =-0.23; P <0.0001) and Ualdo ( r =-0.11; P =0.029). PRA and Ualdo were positively associated with each other ( r =0.5327; P <0.0001) after adjusting for urine potassium, urine sodium, serum potassium, and mean arterial pressure. PRA and Ualdo were lower in women of black race compared with other racial groups ( P <0.001). Our results demonstrate that in women with chronic hypertension PRA and Ualdo increase in early pregnancy and subsequently decrease in women who develop SPE. These findings are consistent with the hypothesis that sodium retention may contribute to the elevation in blood pressure in SPE., (© 2018 American Heart Association, Inc.)
- Published
- 2018
- Full Text
- View/download PDF
24. Renin angiotensin system and its role in biomarkers and treatment in gliomas.
- Author
-
Perdomo-Pantoja A, Mejía-Pérez SI, Gómez-Flores-Ramos L, Lara-Velazquez M, Orillac C, Gómez-Amador JL, and Wegman-Ostrosky T
- Subjects
- Angiotensins chemistry, Brain Neoplasms metabolism, Glioma metabolism, Humans, Peptide Fragments therapeutic use, Renin-Angiotensin System drug effects, Angiotensins therapeutic use, Biomarkers metabolism, Brain Neoplasms therapy, Glioma therapy, Renin-Angiotensin System physiology
- Abstract
Gliomas are the most common primary intrinsic tumor in the brain and are classified as low- or high-grade according to the World Health Organization (WHO). Patients with high-grade gliomas (HGG) who undergo surgical resection with adjuvant therapy have a mean overall survival of 15 months and 100% recurrence. The renin-angiotensin system (RAS), the primary regulator of cardiovascular circulation, exhibits local action and works as a paracrine system. In the context of this local regulation, the expression of RAS peptides and receptors has been detected in different kinds of tumors, including gliomas. The dysregulation of RAS components plays a significant role in the proliferation, angiogenesis, and invasion of these tumors, and therefore in their outcomes. The study and potential application of RAS peptides and receptors as biomarkers in gliomas could bring advantages against the limitations of current tumoral markers and should be considered in the future. The targeting of RAS components by RAS blockers has shown potential of being protective against cancer and improving immunotherapy. In gliomas, RAS blockers have shown a broad spectrum for beneficial effects and are being considered for use in treatment protocols. This review aims to summarize the background behind how RAS plays a role in gliomagenesis and explore the evidence that could lead to their use as biomarkers and treatment adjuvants.
- Published
- 2018
- Full Text
- View/download PDF
25. Control of Energy Expenditure by AgRP Neurons of the Arcuate Nucleus: Neurocircuitry, Signaling Pathways, and Angiotensin.
- Author
-
Morselli LL, Claflin KE, Cui H, and Grobe JL
- Subjects
- Animals, Arcuate Nucleus of Hypothalamus metabolism, Humans, Hypertension metabolism, Neurons metabolism, Obesity metabolism, Signal Transduction physiology, Agouti-Related Protein metabolism, Angiotensins metabolism, Arcuate Nucleus of Hypothalamus physiology, Energy Metabolism physiology, Receptor, Angiotensin, Type 1 metabolism
- Abstract
Purpose of Review: Here, we review the current understanding of the functional neuroanatomy of neurons expressing Agouti-related peptide (AgRP) and the angiotensin 1A receptor (AT
1A ) within the arcuate nucleus (ARC) in the control of energy balance., Recent Findings: The development and maintenance of obesity involves suppression of resting metabolic rate (RMR). RMR control is integrated via AgRP and proopiomelanocortin neurons within the ARC. Their projections to other hypothalamic and extrahypothalamic nuclei contribute to RMR control, though relatively little is known about the contributions of individual projections and the neurotransmitters involved. Recent studies highlight a role for AT1A , localized to AgRP neurons, but the specific function of AT1A within these cells remains unclear. AT1A functions within AgRP neurons to control RMR, but additional work is required to clarify its role within subpopulations of AgRP neurons projecting to distinct second-order nuclei, and the molecular mediators of its signaling within these cells.- Published
- 2018
- Full Text
- View/download PDF
26. Cardiovascular effects of small peptides of the renin angiotensin system.
- Author
-
Moraes PL, Kangussu LM, da Silva LG Jr, Castro CH, Santos RAS, and Ferreira AJ
- Subjects
- Angiotensin-Converting Enzyme 2, Angiotensins chemistry, Animals, Blood Pressure, Coronary Vessels metabolism, Coronary Vessels physiology, Male, Nitric Oxide metabolism, Peptidyl-Dipeptidase A metabolism, Rats, Rats, Inbred SHR, Rats, Wistar, Receptors, G-Protein-Coupled metabolism, Renin-Angiotensin System, Vasodilation, Angiotensins pharmacology, Coronary Vessels drug effects, Peptide Fragments pharmacology
- Abstract
The renin-angiotensin system (RAS) is a unique hormonal cascade which is composed by multiple enzymes and effector peptides. Recently, new peptides presenting biological activity have been discovered, increasing the complexity of the RAS Here, we evaluated the effects of small peptides of the RAS in coronary bed of rats. Firstly, we examined the direct effect of small angiotensinergic peptides [Angiotensin (Ang) -(1-5), Ang-(1-4) Ang-(1-3), and Ang-(1-2)] in coronary vessels. Noteworthy, it was observed that Ang-(1-4), Ang-(1-3), and Ang-(1-2) caused a significant reduction in pressure perfusion. Because Ang-(1-2) was the smallest peptide tested and presented the major effect, we decided to investigate its mechanisms of action. The effect of Ang-(1-2) was partially dependent on the Mas receptor, nitric oxide release and angiotensin-converting enzyme. Importantly, Ang-(1-2) reduced the blood pressure of Wistar rats and SHR Interestingly, SHR presented a more pronounced decrease in blood pressure levels than Wistar rats. Altogether, these data showed that angiotensinergic small peptides hold biological activities in coronary bed of rats., (© 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of The Physiological Society and the American Physiological Society.)
- Published
- 2017
- Full Text
- View/download PDF
27. Crosstalk between angiotensin and the nonamyloidogenic pathway of Alzheimer's amyloid precursor protein.
- Author
-
Kanarek AM, Wagner A, Küppers J, Gütschow M, Postina R, and Kojro E
- Subjects
- Alzheimer Disease metabolism, Alzheimer Disease pathology, Amyloid Precursor Protein Secretases genetics, Amyloid Precursor Protein Secretases metabolism, Amyloid beta-Protein Precursor metabolism, Amyloidosis genetics, Amyloidosis pathology, Angiotensins genetics, Cyclohexanes administration & dosage, GTP-Binding Protein alpha Subunits genetics, GTP-Binding Protein alpha Subunits metabolism, GTP-Binding Protein beta Subunits genetics, GTP-Binding Protein beta Subunits metabolism, GTP-Binding Protein gamma Subunits genetics, GTP-Binding Protein gamma Subunits metabolism, HEK293 Cells, Humans, Proteolysis drug effects, Pyrazines administration & dosage, Receptor, Angiotensin, Type 1 genetics, Receptor, Angiotensin, Type 2 genetics, Receptor, Angiotensin, Type 2 metabolism, beta-Arrestins agonists, beta-Arrestins metabolism, Alzheimer Disease genetics, Amyloid beta-Protein Precursor genetics, Angiotensins metabolism, Receptor, Angiotensin, Type 1 metabolism
- Abstract
The association between hypertension and an increased risk for Alzheimer's disease (AD) and dementia is well established. Many data suggest that modulation of the renin-angiotensin system may be meaningful for the prevention and therapy of neurodegenerative disorders, in particular AD. Proteolytic cleavage of the amyloid precursor protein (APP) by α-secretase precludes formation of neurotoxic Aβ peptides and is expected to counteract the development of AD. An established approach for the up-regulation of α-secretase cleavage is the activation of G protein-coupled receptors (GPCRs). Therefore, our study aimed to analyze whether stimulation of angiotensin AT
1 or AT2 receptors stably expressed in HEK cells influence the nonamyloidogenic pathway of APP processing. Treatment of both receptors with angiotensin II clearly showed that only activation of the AT1 receptor increased several fold the α-secretase-mediated shedding of APP. This effect was completely abolished by treatment with the AT1 receptor-specific antagonist telmisartan. Using the BIM-46187 inhibitor, we demonstrate that the Gαq protein-mediated pathway is involved in this stimulation process. Stimulation of AT1 receptors with the β-arrestin-biased agonist SII was ineffective regarding α-secretase-mediated APP shedding. This result discloses that only the G protein-dependent pathway is involved in the Ang II-induced APP shedding. Blocking of Gβγ subunits by the inhibitor gallein completely prevented constitutive and Ang II-induced APP shedding. Our findings provide evidence that induction of APP shedding via Ang II/AT1 receptor stimulation is effected by G protein activation with Gβγ subunits playing important roles., (© 2017 Federation of European Biochemical Societies.)- Published
- 2017
- Full Text
- View/download PDF
28. Roles of Angiotensin Peptides and Recombinant Human ACE2 in Heart Failure.
- Author
-
Basu R, Poglitsch M, Yogasundaram H, Thomas J, Rowe BH, and Oudit GY
- Subjects
- Acute Disease, Aged, Aged, 80 and over, Case-Control Studies, Chronic Disease, Female, Heart Failure complications, Humans, Male, Middle Aged, Angiotensin Receptor Antagonists therapeutic use, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Angiotensins physiology, Heart Failure blood, Heart Failure therapy
- Abstract
Background: The renin-angiotensin system (RAS) is activated in heart failure (HF) and inhibition of RAS is a mainstay therapy for HF. Angiotensin-converting enzyme 2 (ACE2) and its product, angiotensin 1-7 (Ang-[1-7]), are important negative regulators of the RAS., Objectives: A comprehensive examination of angiotensin peptide levels and therapeutic effects of recombinant human ACE2 (rhACE2) on peptide metabolism was evaluated in human plasma and explanted heart tissue from patients with HF., Methods: Using prospective cohorts with chronic (n = 59) and acute (n = 42) HF, plasma angiotensin analysis was performed using a unique liquid chromatography-mass spectrometry/mass spectroscopy method quantifying circulating and equilibrium levels. Angiotensin II (Ang II) metabolism was examined in human explanted hearts with dilated cardiomyopathy (n = 25)., Results: The dynamic range of the RAS was large, with equilibrium angiotensin levels being 8- to 10-fold higher compared with circulating angiotensin levels. In chronic HF patients receiving ACE inhibition, plasma Ang II was suppressed and plasma Ang-(1-7) was elevated, whereas acute HF and patients receiving angiotensin receptor blocker had higher plasma Ang II with lower Ang-(1-7) levels. Suppressed Ang-(1-7)/Ang II ratio was associated with worsening HF symptoms and longer hospitalization. Recombinant human ACE2 effectively metabolized Ang-(1-10) and Ang II into Ang-(1-9) and Ang-(1-7), respectively. Myocardial Ang II levels in explanted human hearts with dilated cardiomyopathy were elevated despite ACE inhibition with elevated chymase activity, and Ang II was effectively converted to Ang-(1-7) by rhACE2., Conclusions: Plasma angiotensin peptides represent a dynamic network that is altered in HF and in response to rhACE2. An increased plasma Ang-(1-7) level is linked to ACE inhibitor use, whereas acute HF reduced Ang-(1-7) levels and suppressed the Ang-(1-7)/Ang II ratio. Increased chymase activity elevated Ang II levels in failing human hearts. Use of rhACE2 effectively normalized elevated Ang II while increasing Ang-(1-7) and Ang-(1-9) levels., (Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
29. A Primer to Angiotensin Peptide Isolation, Stability, and Analysis by Nano-Liquid Chromatography with Mass Detection.
- Author
-
Olkowicz M, Chlopicki S, and Smolenski RT
- Subjects
- Angiotensins chemistry, Angiotensins isolation & purification, Animals, Atherosclerosis metabolism, Atherosclerosis pathology, Male, Mice, Mice, Inbred C57BL, Peptide Fragments chemistry, Peptide Fragments isolation & purification, Peptidyl-Dipeptidase A metabolism, Protein Stability, Receptors, LDL physiology, Renin-Angiotensin System physiology, Angiotensins analysis, Chromatography, Liquid methods, Nanostructures chemistry, Peptide Fragments analysis, Tandem Mass Spectrometry methods
- Abstract
The renin-angiotensin system (RAS) is an important element of cardiovascular and renal physiology and targeting the RAS by renin inhibitors, angiotensin (Ang) converting enzyme (ACE) inhibitors and Ang II type 1 receptor antagonists is effective in the treatment of hypertension, heart failure, and atherosclerosis. Quantification of Ang peptides is critical to establish the status of the RAS, but it is challenging due to low Ang peptides concentrations (fmol/mL or fmol/g), abundance of interfering substances, post sampling conversions, and difficulties with the specificity of the assay.In this chapter, we describe a new nano-LC/MS-based methodology for comprehensive, specific, sensitive, and accurate quantification of Ang peptides profile in plasma and tissue. We optimized sample pretreatment method (protein removal (acetonitrile precipitation) followed by solid-phase extraction (C18 silica bonded phase)), chromatographic conditions (reversed-phase nanochromatography with preconcentration), and mass detection (multiple reaction monitoring) of nine peptides: Ang-(1-12), Ang I (1-10), Ang-(1-9), Ang II (1-8), [Ala
1 ]-Ang II, Ang III (2-8), Ang IV (3-8), Ang-(1-7), and [Ala1 ]-Ang-(1-7). Assessment of plasma and cardiac concentrations of Ang peptides in genetically modified atherosclerotic apolipoprotein E/LDL receptor double knockout (ApoE-/- /LDLR-/- ) mice vs. wild types revealed changes in renin-angiotensin system consistent with an overactivation of ACE and impairment of ACE2. The method could be easily adopted for high-throughput analysis and for use in clinical applications such as diagnosis of the RAS abnormalities or monitoring of the RAS inhibition-based therapies.- Published
- 2017
- Full Text
- View/download PDF
30. Fluorescence-Based Binding Assay for Screening Ligands of Angiotensin Receptors.
- Author
-
Bragina ME, Stergiopulos N, and Fraga-Silva RA
- Subjects
- Animals, Binding, Competitive, CHO Cells, Cricetulus, Ligands, Protein Binding, Angiotensins metabolism, Fluorescence, Fluorescent Dyes chemistry, Receptors, Angiotensin analysis
- Abstract
Binding assay is a common technique used to characterize ability of a ligand to interact with a specific biological target. A number of parameters, such as binding affinity, receptor density, and association/dissociation rate constants, can be measured by means of this technique. In most cases, implementation of the binding assay requires specific infrastructure for labeling and detecting the ligand, which impedes realization of this technique in a standard laboratory. Here we describe a simple fluorescence-based binding assay for angiotensin peptides and receptors, which does not require complex equipment and can be used for initial screening of the novel ligands or mutational studies.
- Published
- 2017
- Full Text
- View/download PDF
31. Analysis of Angiotensin Metabolism in the Kidney Using Mass Spectrometry.
- Author
-
Grobe N and Elased KM
- Subjects
- Animals, Mice, Software, Angiotensins metabolism, Kidney metabolism, Peptide Fragments metabolism, Renin-Angiotensin System physiology, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization methods
- Abstract
The renin angiotensin system (RAS) is a highly complex enzymatic system consisting of multiple peptide hormones, enzymes, and receptors. A thorough characterization of angiotensin peptide metabolism is crucial for understanding pathological states associated with an imbalanced RAS. Here, we describe two matrix-assisted laser desorption/ionization (MALDI) mass spectrometric (MS) approaches for the assessment of in vitro and in situ RAS enzymatic activities in the kidney using the natural angiotensin peptide substrates. These MS techniques demonstrate high specificity and are superior over conventional spectrophotometric or colorimetric assays since multiple proteolytic cleavage sites can be detected, thus unraveling the complexity of the RAS.
- Published
- 2017
- Full Text
- View/download PDF
32. Characterization of key genes of the renin-angiotensin system in mature feline adipocytes and during in vitro adipogenesis.
- Author
-
Riedel J, Badewien-Rentzsch B, Kohn B, Hoeke L, and Einspanier R
- Subjects
- Adipose Tissue cytology, Animals, Female, RNA, Messenger genetics, RNA, Messenger metabolism, Real-Time Polymerase Chain Reaction, Renin metabolism, Adipocytes physiology, Angiotensins metabolism, Cats physiology, Gene Expression Regulation physiology, Renin-Angiotensin System physiology
- Abstract
Obesity is a growing health problem in humans as well as companion animals. In the development and progression of obesity-associated diseases, the members of the renin-angiotensin system (RAS) are proposed to be involved. Particularly, the prevalence of type 2 diabetes mellitus in cats has increased enormously which is often been linked to obesity as well as to RAS. So far, reports about the expression of a local RAS in cat adipocytes are missing. Therefore, we investigated the mRNA expression of various RAS genes as well as the adipocyte marker genes adiponectin, leptin and PPAR-γ in feline adipocytes using quantitative PCR. To characterize the gene expression during adipogenesis, feline pre-adipocytes were differentiated into adipocytes in a primary cell culture and the expression of RAS key genes measured. All major RAS components were expressed in feline cells, but obvious differences in the expression between pre-adipocytes and the various differentiation stages were found. Interestingly, the two enzymes ACE and ACE2 showed an opposite expression course. In addition to the in vitro experiments, mature adipocytes were isolated from subcutaneous and visceral adipose tissue. Significant differences between both fat depots were found for ACE as well as AT1 receptor with greater expression in subcutaneous than in visceral adipocytes. Visceral adipocytes had significantly higher adiponectin and PPAR-γ mRNA level compared to the subcutaneous fat cells. Concerning the nutritional status, a significant lower expression of ACE2 was measured in subcutaneous adipocytes of overweight cats. In summary, the results show the existence of a potentially functional local RAS in feline adipose tissue which is differentially regulated during adipogenesis and dependent on the fat tissue depot and nutritional status. These findings are relevant for understanding the development of obesity-associated diseases in cats such as diabetes mellitus., (Journal of Animal Physiology and Animal Nutrition © 2015 Blackwell Verlag GmbH.)
- Published
- 2016
- Full Text
- View/download PDF
33. Peripheral levels of angiotensins are associated with depressive symptoms in Parkinson's disease.
- Author
-
Rocha NP, Scalzo PL, Barbosa IG, de Campos-Carli SM, Tavares LD, de Souza MS, Christo PP, Reis HJ, Simões E Silva AC, and Teixeira AL
- Subjects
- Aged, Case-Control Studies, Female, Humans, Male, Middle Aged, Peptidyl-Dipeptidase A blood, Psychiatric Status Rating Scales, Statistics as Topic, Angiotensins blood, Depressive Disorder blood, Depressive Disorder etiology, Parkinson Disease complications
- Abstract
Background: The pathogenesis of PD remains elusive. The renin-angiotensin-system (RAS) has recently been implicated in the degeneration of dopaminergic neurons. This study aimed to compare plasma levels of components of the RAS of individuals with PD with controls. We also investigated the association between these circulating markers and motor, depressive and cognitive parameters., Methods: Thirty PD patients and twenty controls were subjected to clinical evaluation, including cognitive and depressive symptoms assessment. Plasma levels of Angiotensin (Ang) I, Ang II, Ang- (1-7), angiotensin-converting enzyme (ACE) and ACE2 were measured by Enzyme-Linked Immunosorbent Assay (ELISA)., Results: PD patients presented lower plasma levels of Ang I, Ang II and Ang- (1-7) than control individuals. Among PD patients, lower circulating levels of angiotensins were associated with increased severity of depressive symptoms., Conclusions: This is the first study showing that peripheral levels of RAS components are changed in PD and associated with depressive symptoms., (Copyright © 2016. Published by Elsevier B.V.)
- Published
- 2016
- Full Text
- View/download PDF
34. Gastrointestinal potassium binding-more than just lowering serum [K(+)]: patiromer, potassium balance, and the renin angiotensin aldosterone axis.
- Author
-
Emmett M and Mehta A
- Subjects
- Aldosterone, Humans, Hyperkalemia blood, Polymers, Renin, Renin-Angiotensin System, Angiotensins, Potassium blood
- Abstract
Hyperkalemia limits the use of renin-angiotensin-aldosterone axis (RAAS) blockers in patients with renal insufficiency. This can be managed by efforts to increase kaliuresis and by gastrointestinal potassium binding with sodium polystyrene sulfonate, a relatively ineffective agent. Now with the availability of patiromer, RAAS blockers can be used more liberally. In addition, potassium reduction decreases aldosterone, which may be beneficial. Adverse nonepithelial aldosterone effects such as endothelial dysfunction and cardiac fibrosis may be ameliorated., (Copyright © 2016 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
35. Angiotensin A/Alamandine/MrgD Axis: Another Clue to Understanding Cardiovascular Pathophysiology.
- Author
-
Hrenak J, Paulis L, and Simko F
- Subjects
- Humans, Angiotensins metabolism, Cardiovascular Diseases physiopathology, Oligopeptides metabolism, Receptors, G-Protein-Coupled metabolism
- Abstract
The renin-angiotensin system (RAS) plays a crucial role in cardiovascular regulations and its modulation is a challenging target for the vast majority of cardioprotective strategies. However, many biological effects of these drugs cannot be explained by the known mode of action. Our comprehension of the RAS is thus far from complete. The RAS represents an ingenious system of "checks and balances". It incorporates vasoconstrictive, pro-proliferative, and pro-inflammatory compounds on one hand and molecules with opposing action on the other hand. The list of these molecules is still not definitive because new biological properties can be achieved by minor alteration of the molecular structure. The angiotensin A/alamandine-MrgD cascade associates the deleterious and protective branches of the RAS. Its identification provided a novel clue to the understanding of the RAS. Angiotensin A (Ang A) is positioned at the "crossroad" in this system since it either elicits direct vasoconstrictive and pro-proliferative actions or it is further metabolized to alamandine, triggering opposing effects. Alamandine, the central molecule of this cascade, can be generated both from the "deleterious" Ang A as well as from the "protective" angiotensin 1-7. This pathway modulates peripheral and central blood pressure regulation and cardiovascular remodeling. Further research will elucidate its interactions in cardiovascular pathophysiology and its possible therapeutic implications.
- Published
- 2016
- Full Text
- View/download PDF
36. Plasma and Kidney Angiotensin Peptides: Importance of the Aminopeptidase A/Angiotensin III Axis.
- Author
-
Wysocki J, Ye M, and Batlle D
- Subjects
- Angiotensin-Converting Enzyme 2, Animals, Female, Male, Mice, Inbred C57BL, Mice, Knockout, Angiotensins blood, Glutamyl Aminopeptidase metabolism, Kidney metabolism, Peptidyl-Dipeptidase A metabolism, Renin-Angiotensin System
- Abstract
Background: The renin-angiotensin system is a complex regulatory hormonal network with a main biological peptide and therapeutic target, angiotensin (Ang) II (1-8). There are other potentially important Ang peptides that have not been well evaluated., Methods: Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used for concurrent evaluation of multiple Angs downstream of Ang I (1-10) and Ang II (1-8) in kidney and plasma from wild-type (WT) mice. Angiotensin converting enzyme 2 knockout (ACE2KO) was also used as a way to examine the Angs profile in the absence of ACE2, an enzyme that cleaves both Ang I (1-10) and Ang II (1-8)., Results: In plasma from both WT and ACE2KO, levels of Ang I (1-10), Ang III (2-8), and Ang (2-10) were the highest of all the renin-angiotensin system (RAS) peptides. The latter two peptides are products of aminopeptidase A cleavage of Ang II (1-8) and Ang I (1-10), respectively. In contrast, plasma levels of Ang II (1-8), and Ang (1-7), the product of Ang II (1-8) cleavage by ACE2, were low. In kidney from both WT and ACE2KO, Ang II (1-8) levels were high as compared to plasma levels. In the ACE2KO mice, a significant increase in either Ang II (1-8) or a decrease in Ang (1-7) was not observed in plasma or in the kidney., Conclusion: RAS-focused peptidomic approach revealed major differences in Ang peptides between mouse plasma and kidney. These Ang peptide profiles show the dominance of the aminopeptidase A/Ang (2-10) and aminopeptidase A/Ang III (2-8) pathways in the metabolism of Ang I (1-10) and Ang II (1-8) over the ACE2/Ang (1-7) axis. Ang III (2-8) and other peptides formed from aminopeptidase A cleavage may be important therapeutic RAS targets., (© American Journal of Hypertension, Ltd 2015. All rights reserved. For Permissions, please email: journals.permissions@oup.com.)
- Published
- 2015
- Full Text
- View/download PDF
37. Development of a sensitive, accurate and robust liquid chromatography/mass spectrometric method for profiling of angiotensin peptides in plasma and its application for atherosclerotic mice.
- Author
-
Olkowicz M, Radulska A, Suraj J, Kij A, Walczak M, Chlopicki S, and Smolenski RT
- Subjects
- Angiotensin I blood, Angiotensin II blood, Angiotensin III blood, Animals, Apolipoproteins E genetics, Atherosclerosis genetics, Chromatography, Liquid methods, Mass Spectrometry methods, Mice, Inbred C57BL, Mice, Knockout, Peptide Fragments blood, Receptors, LDL genetics, Angiotensins blood, Atherosclerosis blood
- Abstract
Quantification of angiotensin (Ang) peptides in biological matrices is a challenge due to their low picomolar (pM) concentration and poor analytical performance of current methods. This work aimed to select an optimal strategy for liquid chromatography/mass spectrometry (LC/MS) quantification of major angiotensins in plasma of wild type and atherosclerotic mice. Optimal LC/MS set-up for Ang quantification was chosen, based on analytical performance, from: nanoflow/orbitrap, nanoflow/triple quadrupole and preconcentration nanoflow/triple quadrupole. The best LC/MS configuration (preconcentration nanoflow/triple quadrupole) was validated and used for measurement of angiotensins (Ang I, II, III, IV and (1-7)) in plasma of 6-month-old atherosclerotic apolipoprotein E/LDL receptor double knock-outs (ApoE/LDLR (--/--)) and wild type C57BL/6J (WT) mice. The method established for Ang quantification was selective, accurate and highly sensitive with LLOQ of 5pgmL(-1). The peak area intra-day precisions for Ang II and Ang-(1-7) were in the range 3.0-5.1 and 3.5-5.8, respectively, with corresponding accuracy of 95.4-103.5% and 95.6-106.3%. Plasma angiotensin profile was substantially modified in ApoE/LDLR knock-out mice with increase in concentration of Ang II from 37.6±21.3pgmL(-1) in WT to 200.2±47.6pgmL(-1). Concentrations of Ang I, III and IV were also increased 3-10 fold in ApoE/LDLR (--/--) mice while that of Ang-(1-7) was unchanged. We conclude that the method developed could be effectively used for accurate, comprehensive profiling of angiotensin peptides in mouse plasma. We identified substantial changes in renin-angiotensin system in a genetic mouse model of atherosclerosis consistent with the overactivation of angiotensin converting enzyme (ACE) and the impairment of ACE2., (Copyright © 2015 Elsevier B.V. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
38. [History of the renin-angiotensin system: great men, a great finding].
- Author
-
Cherne PN and Young P
- Subjects
- Argentina, History, 19th Century, History, 20th Century, Humans, United States, Angiotensins history, Renin-Angiotensin System, Research Personnel history
- Abstract
The discovery of the renin-angiotensin-aldosterone system (RAS) was one of the important findings in physiology. Two research groups, in both North and South America, independently discovered that renin released a novel vasopressor agent. The Argentine group named it hypertensin, and called hypertensinogen to its plasma protein substrate. The group from the United States named it angiotonin. In 1958, Braun Menendez and Irvine Page suggested that the peptide's name should be angiotensin. Development of angiotensin converting enzyme (ACE) inhibitors proved that the RAS is effective in controlling hypertension and heart failure, and in preventing vascular injury in chronic diseases. Both teams, showing that beyond being great investigators they were remarkable persons, shared the merit of the discovery.
- Published
- 2014
- Full Text
- View/download PDF
39. The ACE2/Ang-(1-7)/Mas axis can inhibit hepatic insulin resistance.
- Author
-
Cao X, Yang FY, Xin Z, Xie RR, and Yang JK
- Subjects
- Angiotensin-Converting Enzyme 2, Angiotensins genetics, Animals, Blotting, Western, Cells, Cultured, Flow Cytometry, Hep G2 Cells, Humans, MAP Kinase Kinase 4 metabolism, Mice, Models, Biological, Peptidyl-Dipeptidase A genetics, Rats, Reactive Oxygen Species antagonists & inhibitors, Real-Time Polymerase Chain Reaction, Signal Transduction, Angiotensins metabolism, Insulin Resistance genetics, Peptidyl-Dipeptidase A metabolism
- Abstract
Blocking the renin-angiotensin system (RAS) can reduce the risk of diabetes. Meanwhile, the angiotensin (Ang)-converting enzyme-2 (ACE2)/Ang-(1-7)/Mas axis has recently been proposed to function as a negative regulator of the RAS. In previous studies, we first demonstrated that ACE2 knockout (ACE2(-/)(y)) mice exhibit impaired glucose tolerance or diabetes. However the precise roles of ACE2 on glucose metabolism are unknown. Here we show that the ACE2/Ang-(1-7)/Mas axis can ameliorate insulin resistance in the liver. Activation of the ACE2/Ang-(1-7)/Mas axis increases glucose uptake and decreases glycogen synthesis in the liver accompanied by increased expression of glucose transporters, insulin receptor substrates and decreased expression of enzymes for glycogen synthesis. ACE2 knockout mice displayed elevated levels of oxidative stress and exposure to Ang-(1-7) reduced the stress in hepatic cells. As a consequence of anti-oxidative stress, activation of the ACE2/Ang-(1-7)/Mas axis led to improved hepatic insulin resistance through the Akt/PI3K/IRS-1/JNK insulin signaling pathway. This is the first time documented that the ACE2/Ang-(1-7)/Mas axis can ameliorate insulin resistance in the liver. As insulin resistance in the liver is considered to be the primary cause of the development of type 2 diabetes, this axis may serve as a new diabetes target., (Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
40. Methylglyoxal, a reactive glucose metabolite, increases renin angiotensin aldosterone and blood pressure in male Sprague-Dawley rats.
- Author
-
Dhar I, Dhar A, Wu L, and Desai KM
- Subjects
- Angiotensins genetics, Animals, Antihypertensive Agents pharmacology, Biomarkers blood, Catecholamines blood, Cells, Cultured, Disease Models, Animal, Hypertension blood, Hypertension drug therapy, Hypertension genetics, Hypertension physiopathology, Male, NF-kappa B metabolism, RNA Interference, RNA, Messenger metabolism, Rats, Rats, Sprague-Dawley, Receptor for Advanced Glycation End Products, Receptors, Immunologic genetics, Receptors, Immunologic metabolism, Renin genetics, Signal Transduction, Thiazoles pharmacology, Time Factors, Up-Regulation, Aldosterone blood, Angiotensins blood, Blood Pressure drug effects, Hypertension chemically induced, Pyruvaldehyde, Renin blood, Renin-Angiotensin System
- Abstract
Background: The majority of people with diabetes develop hypertension along with increased activity of the renin-angiotensin system. Methylglyoxal, a reactive glucose metabolite, is elevated in diabetic patients. We investigated the effects of methylglyoxal on the renin-angiotensin system and blood pressure., Methods: Male Sprague-Dawley rats were treated with a continuous infusion of methylglyoxal with a minipump for 4 weeks. Organs/tissues and cultured vascular smooth muscle cells (VSMCs) were used for molecular studies. High-performance liquid chromatography, Western blotting, and quantitative real-time polymerase chain reaction were used to measure methylglyoxal, proteins, and mRNA, respectively. Small interfering RNA for angiotensinogen and the receptor for advanced glycation endproducts (RAGE) were used to study mechanisms., Results: Methylglyoxal-treated rats developed a significant increase in blood pressure and plasma levels of aldosterone, renin, angiotensin, and catecholamines. Methylglyoxal level and protein and mRNA for angiotensin, AT1 receptor, adrenergic α1D receptor, and renin were significantly increased in the aorta and/or kidney of methylglyoxal-treated rats, a novel finding. Alagebrium attenuated the above effects of methylgloyxal. Treatment of cultured VSMCs with methylglyoxal or high glucose (25 mM) significantly increased cellular methylglyoxal and protein and mRNA for nuclear factor kappa B (NF-κB), angiotensin, AT1 receptor, and α1D receptor, which were prevented by inhibition of NF-κB, and by alagebrium. Silencing of mRNA for RAGE prevented the increase in NF-kB induced by methylglyoxal. Silencing of mRNA for angiotensinogen prevented the increase in NF-κB, angiotensin, AT1 receptor, and α1D receptor., Conclusions: Methylglyoxal activates NF-κB through RAGE and thereby increases renin-angiotensin levels, a novel finding, and a probable mechanism of increase in blood pressure.
- Published
- 2014
- Full Text
- View/download PDF
41. Impact of the renin-angiotensin system on cardiac energy metabolism in heart failure.
- Author
-
Mori J, Zhang L, Oudit GY, and Lopaschuk GD
- Subjects
- Angiopoietins metabolism, Angiotensin II metabolism, Angiotensin II pharmacology, Angiotensin-Converting Enzyme 2, Angiotensin-Converting Enzyme Inhibitors pharmacology, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Angiotensins pharmacology, Animals, Carbohydrate Metabolism, Fatty Acids metabolism, Heart drug effects, Heart physiopathology, Heart Failure drug therapy, Humans, Insulin Resistance, Mitochondria drug effects, Mitochondria metabolism, Oxidation-Reduction, Peptidyl-Dipeptidase A metabolism, Renin-Angiotensin System drug effects, Angiotensins metabolism, Energy Metabolism, Heart Failure metabolism, Myocardium metabolism, Renin metabolism
- Abstract
The renin-angiotensin system (RAS) plays a key pathogenic role in heart failure. The adverse effects of angiotensin II (Ang II), a major player of the RAS, contributes to the development of heart failure. Heart failure is accompanied by significant perturbations in cardiac energy metabolism that can both decrease cardiac energy supply and decrease cardiac efficiency. Recent evidence suggests that Ang II might be involved in these perturbations in cardiac energy metabolism. Furthermore, new components of the RAS, such as angiotensin converting enzyme 2 and Ang1-7, have been reported to exert beneficial effects on cardiac energy metabolism. As a result, a further understanding of the relationship between the RAS and cardiac energy metabolism has the potential to improve the control of heart failure, and may lead to the development of new therapies to treat heart failure. This review summarizes what effects the RAS has on cardiac energy metabolism, highlighting how Ang II can induce cardiac insulin resistance and mitochondrial damage, and what role reactive oxygen species and sirtuins have on these processes., (© 2013.)
- Published
- 2013
- Full Text
- View/download PDF
42. Dopamine-angiotensin interactions in the basal ganglia and their relevance for Parkinson's disease.
- Author
-
Labandeira-Garcia JL, Rodriguez-Pallares J, Dominguez-Meijide A, Valenzuela R, Villar-Cheda B, and Rodríguez-Perez AI
- Subjects
- Brain physiopathology, Data Interpretation, Statistical, Humans, Neostriatum physiopathology, Paracrine Communication physiology, Substantia Nigra physiopathology, Angiotensins physiology, Basal Ganglia physiology, Dopamine physiology, Parkinson Disease physiopathology, Renin-Angiotensin System physiology
- Abstract
Renin-angiotensin systems are known to act in many tissues, for example, the blood vessel wall or kidney, where a close interaction between angiotensin and dopamine has been demonstrated. Regulatory interactions between the dopaminergic and renin-angiotensin systems have recently been described in the substantia nigra and striatum. In animal models, dopamine depletion induces compensatory overactivation of the local renin-angiotensin system, which primes microglial responses and neuron vulnerability by activating NADPH-oxidase. Hyperactivation of the local renin-angiotensin system exacerbates the inflammatory microglial response, oxidative stress, and dopaminergic degeneration, all of which are inhibited by angiotensin receptor blockers and inhibitors of angiotensin-converting enzymes. In this review we provide evidence suggesting that the renin-angiotensin system may play an important role in dopamine's mediated neuroinflammation and oxidative stress changes in Parkinson's disease. We suggest that manipulating brain angiotensin may constitute an effective neuroprotective strategy for Parkinson's disease., (© 2013 International Parkinson and Movement Disorder Society.)
- Published
- 2013
- Full Text
- View/download PDF
43. Urinary renin and angiotensinogen in type 2 diabetes: added value beyond urinary albumin?
- Author
-
Persson F, Lu X, Rossing P, Garrelds IM, Danser AH, and Parving HH
- Subjects
- Adult, Aged, Aged, 80 and over, Amides therapeutic use, Angiotensinogen blood, Angiotensinogen urine, Antihypertensive Agents therapeutic use, Biphenyl Compounds therapeutic use, Cross-Over Studies, Diabetes Mellitus, Type 2 blood, Double-Blind Method, Female, Fumarates therapeutic use, Humans, Irbesartan, Male, Middle Aged, Renin blood, Renin-Angiotensin System, Tetrazoles therapeutic use, Albumins analysis, Angiotensins urine, Diabetes Mellitus, Type 2 urine, Renin urine
- Abstract
Objective: Urinary levels of renin-angiotensin-aldosterone system (RAAS) components may reflect renal RAAS activity and/or the renal efficacy of RAAS inhibition. Our aim was to determine whether urinary angiotensinogen and renin are circulating RAAS-independent markers during RAAS blockade., Methods: Urinary and plasma levels of angiotensinogen, renin, and albumin were measured in 22 patients with type 2 diabetes, hypertension, and albuminuria, during 2-month treatment periods with placebo, aliskiren, irbesartan, or their combination in random order in a crossover study., Results: Aliskiren and irbesartan both increased plasma renin 3-4-fold, and above 10-fold when combined. Irbesartan decreased plasma angiotensinogen by approximately 25%, and no changes in plasma angiotensinogen were observed during the combination. Urine contained aliskiren at micromolar levels, blocking urinary renin by above 90%. Both blockers reduced urinary angiotensinogen, significant for irbesartan only. Combination blockade reduced urinary angiotensinogen even further. Reductions in urinary angiotensinogen paralleled albuminuria changes, and the urine/plasma concentration ratio of angiotensinogen was identical to that of albumin under all conditions. In contrast, urinary renin did not follow albumin, and remained unaltered after all treatments. Yet, the urine/plasma concentration ratio of renin was more than 100-fold higher than that of angiotensinogen and albumin, and approximately 4-fold reduced by single RAAS blockade, and more than 10-fold by dual RAAS blockade., Conclusions: Aliskiren filters into urine and influences urinary renin measurements. The urine/plasma renin ratio, but not urinary renin alone, may reflect the renal efficacy of RAAS blockade. Urinary angiotensinogen is a marker of filtration barrier damage rather than intrarenal RAAS activity.
- Published
- 2013
- Full Text
- View/download PDF
44. Subcellular characteristics of functional intracellular renin-angiotensin systems.
- Author
-
Abadir PM, Walston JD, and Carey RM
- Subjects
- Animals, Humans, Angiotensins metabolism, Renin metabolism, Renin-Angiotensin System
- Abstract
The renin-angiotensin system (RAS) is now regarded as an integral component in not only the development of hypertension, but also in physiologic and pathophysiologic mechanisms in multiple tissues and chronic disease states. While many of the endocrine (circulating), paracrine (cell-to-different cell) and autacrine (cell-to-same cell) effects of the RAS are believed to be mediated through the canonical extracellular RAS, a complete, independent and differentially regulated intracellular RAS (iRAS) has also been proposed. Angiotensinogen, the enzymes renin and angiotensin-converting enzyme (ACE) and the angiotensin peptides can all be synthesized and retained intracellularly. Angiotensin receptors (types I and 2) are also abundant intracellularly mainly at the nuclear and mitochondrial levels. The aim of this review is to focus on the most recent information concerning the subcellular localization, distribution and functions of the iRAS and to discuss the potential consequences of activation of the subcellular RAS on different organ systems., (Copyright © 2012 Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
45. Mass spectrometry for the molecular imaging of angiotensin metabolism in kidney.
- Author
-
Grobe N, Elased KM, Cool DR, and Morris M
- Subjects
- Angiotensin II chemistry, Angiotensin II metabolism, Angiotensin III chemistry, Angiotensin III metabolism, Angiotensins chemistry, Animals, Image Processing, Computer-Assisted, Kidney anatomy & histology, Kidney drug effects, Kidney Cortex anatomy & histology, Kidney Cortex drug effects, Kidney Cortex metabolism, Kidney Medulla anatomy & histology, Kidney Medulla drug effects, Kidney Medulla metabolism, Kinetics, Male, Mice, Mice, Inbred C57BL, Osmolar Concentration, Peptide Fragments chemistry, Peptide Fragments metabolism, Protease Inhibitors pharmacology, Proteolysis drug effects, Renin-Angiotensin System, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Angiotensins metabolism, Kidney metabolism, Molecular Imaging methods
- Abstract
To better understand the tissue distribution and activity of enzymes involved in angiotensin II (Ang II) processing, we developed a novel molecular imaging method using matrix-assisted laser desorption ionization-time-of-flight (MALDI-TOF) mass spectrometry. Mouse kidney sections (12 μm) were incubated with 10-1,000 μmol/l Ang II for 5-15 min at 37°C. The formed peptides Ang III and Ang-(1-7) were identified by MALDI-TOF/TOF. A third metabolite, Ang-(1-4), was generated from further degradation of Ang-(1-7). Enzymatic processing of Ang II was dose and time dependent and absent in heat-treated kidney sections. Distinct spatial distribution patterns (pseudocolor images) were observed for the peptides. Ang III was localized in renal medulla, whereas Ang-(1-7)/Ang-(1-4) was present in cortex. Regional specific peptide formation was confirmed using microdissected cortical and medullary biopsies. In vitro studies with recombinant enzymes confirmed activity of peptidases known to generate Ang III or Ang-(1-7) from Ang II: aminopeptidase A (APA), Ang-converting enzyme 2 (ACE2), prolyl carboxypeptidase (PCP), and prolyl endopeptidase (PEP). Renal medullary Ang III generation was blocked by APA inhibitor glutamate phosphonate. The ACE2 inhibitor MLN-4760 and PCP/PEP inhibitor Z-pro-prolinal reduced cortical Ang-(1-7) formation. Our results establish the power of MALDI imaging as a highly specific and information-rich analytical technique that will further aid our understanding of the role and site of Ang II processing in cardiovascular and renal pathologies.
- Published
- 2012
- Full Text
- View/download PDF
46. Renin is an angiotensin-independent profibrotic mediator: role in pulmonary fibrosis.
- Author
-
Montes E, Ruiz V, Checa M, Maldonado V, Melendez-Zajgla J, Montaño M, Ordoñez-Razo R, Cisneros J, García-de-Alba C, Pardo A, and Selman M
- Subjects
- Cells, Cultured cytology, Collagen metabolism, Fibroblasts cytology, Fibrosis, Gene Expression Regulation, Humans, Matrix Metalloproteinase 2 metabolism, RNA, Small Interfering metabolism, Recombinant Proteins metabolism, Renin biosynthesis, Renin-Angiotensin System, Transforming Growth Factor beta1 metabolism, Angiotensins metabolism, Lung metabolism, Pulmonary Fibrosis metabolism, Renin blood
- Abstract
The pathogenesis of idiopathic pulmonary fibrosis (IPF) is probably the result of interplay between cytokines/chemokines and growth factors. The renin-angiotensin (Ang) system is involved, although its profibrotic effect is attributed to Ang II. However, recent studies suggest that renin, through a specific receptor, is implicated in fibrogenesis. In this study, the expression of renin and renin receptor was examined in normal and IPF lungs and fibroblasts. Normal human lung fibroblasts were stimulated with renin or transfected with renin small interfering RNA (siRNA), and the expression of transforming growth factor (TGF)-β1 and α-1-type I collagen was analysed. Normal lungs and lung fibroblasts expressed renin, which was strongly upregulated in IPF lungs and fibroblasts (∼10-fold increase; p<0.05). Immunocytochemistry showed intense renin staining in IPF fibroblasts. Renin-stimulated lung fibroblasts displayed an increase in the expression of TGF-β1 (mean ± sd 1.8 × 10(3) ± 0.2 × 10(3) versus 1.2 × 10(3)± 0.3 × 10(3) mRNA copies per 18S ribosomal RNA; p<0.01) and collagen (5.93 × 10(2)± 0.66 × 10(2) versus 3.28 × 10(2) ± 0.5 × 10(2); p<0.01), while knocking down renin expression using siRNA provoked a strong decrease of both molecules. These effects were independent of Ang II, since neither losartan nor captopril decreased these effects. Renin also decreased matrix metalloprotease-1 expression and induced TGF-β1 activation (163 ± 34 versus 110 ± 15 pg active TGF-β1 per mg total protein). These findings highlight the possible role of renin as an Ang II-independent profibrotic factor in lung fibrosis.
- Published
- 2012
- Full Text
- View/download PDF
47. [Renin-angiotensin-aldosteron system: evolution of views from renin discovery to nowadays. Perspectives of therapeutic block].
- Author
-
Shestakova MV
- Subjects
- Angiotensins drug effects, Humans, Hypertension blood, Renin drug effects, Aldosterone blood, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Angiotensins blood, Hypertension drug therapy, Mineralocorticoid Receptor Antagonists therapeutic use, Renin blood, Renin-Angiotensin System
- Abstract
Recent revolution in the knowledge about structure, physiological and pathophysiological effects of renin-angiotensin-aldosteron system (RAAS) took place recently when it was discovered that local synthesis of all the RAAS components occurs in target organs and their tissues (the heart, kidneys, vessels, brain tissues). It was found that besides classic RAAS acting via activation of angiotensin II (Ang-II) and its receptors, there is an alternative RAAS opposed to atherogenic potential of Ang-II. Renin and prorenin are shown to have both enzymatic and hormonal activities. Wider understanding appeared of extrarenal effects of aldosteron, its non-genomic activity. The above discoveries open new opportunities for pharmacological regulation of RAAS activity, which enables more effectively correct overactivity of this system in organs at risk of negativeAng-II impact.
- Published
- 2011
48. 20-hydroxyeicosatetraenoic acid and angiotensin: a positive feedback system to cause hypertension.
- Author
-
Imig JD
- Subjects
- Animals, Hypertension metabolism, Rats, Renin-Angiotensin System, Angiotensins metabolism, Hydroxyeicosatetraenoic Acids metabolism, Hypertension etiology
- Published
- 2010
- Full Text
- View/download PDF
49. Renin-angiotensin system inhibitors in proteinuric chronic kidney disease.
- Author
-
Hirsch S
- Subjects
- Angiotensin II Type 2 Receptor Blockers, Angiotensin-Converting Enzyme Inhibitors pharmacology, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Antihypertensive Agents adverse effects, Antihypertensive Agents pharmacology, Humans, Kidney Failure, Chronic drug therapy, Kidney Failure, Chronic prevention & control, Mineralocorticoid Receptor Antagonists pharmacology, Mineralocorticoid Receptor Antagonists therapeutic use, Renal Insufficiency, Chronic urine, Renin-Angiotensin System, Angiotensins antagonists & inhibitors, Antihypertensive Agents therapeutic use, Proteinuria drug therapy, Renal Insufficiency, Chronic drug therapy, Renin antagonists & inhibitors
- Abstract
Renin-angiotensin inhibitors are effective in slowing the progression of chronic proteinuric kidney disease. These medicines should be used in preference to anti-hypertensives that do not provide renoprotection.
- Published
- 2009
50. Characterization of renin-angiotensin system enzyme activities in cultured mouse podocytes.
- Author
-
Burns KD and Li N
- Subjects
- Animals, Cells, Cultured, Mice, Renin-Angiotensin System, Angiotensins chemistry, Podocytes chemistry
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.